Literature DB >> 16958787

Interspecies allometric scaling. Part I: prediction of clearance in large animals.

I Mahmood1, M Martinez, R P Hunter.   

Abstract

Interspecies scaling is a useful tool for the prediction of pharmacokinetic parameters from animals to humans, and it is often used for estimating a first-time in human dose. The knowledge of pharmacokinetics in veterinary species is important for dosage selection, particularly in the treatment of large zoo animal species, such as elephants, giant cats and camels, for which pharmacokinetic data are scant. Therefore, the accuracy in clearance predictions in large animal species, with and without the use of correction factors (rule of exponents), and the impact of species selection in the prediction of clearance in large animal species was examined. Based upon this analysis, it was determined that there is a much larger risk of inaccuracies in the clearance estimates in large animal species when compared with that observed for humans. Unlike in humans, for large animal species, correction factors could not be applied because there was no trend between the exponents of simple allometry and the appropriate correction factor for improving our predictions. Nevertheless, we did see an indication that the exponents of simple allometry may alert us as to when the predicted clearance in the large animal may be underestimated or overpredicted. For example, if a large animal is included in the scaling, the predicted clearance in a large animal should be considered overestimated if the exponent of simple allometry is >1.3. Despite the potential for extrapolation error, the reality is that allometric scaling is needed across many veterinary practice situations, and therefore will be used. For this reason, it is important to consider mechanisms for reducing the risk of extrapolation errors that can seriously affect target animal safety, therapeutic response, or the accuracy of withdrawal time predictions.

Entities:  

Mesh:

Year:  2006        PMID: 16958787     DOI: 10.1111/j.1365-2885.2006.00786.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  11 in total

1.  Allometric prediction of the human pharmacokinetic parameters for naveglitazar.

Authors:  Preeti Ahlawat; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

2.  Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus).

Authors:  Leann M Tana; Ramiro Isaza; David E Koch; Robert P Hunter
Journal:  J Zoo Wildl Med       Date:  2010-09       Impact factor: 0.776

Review 3.  Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey.

Authors:  Carl Petersson; Xin Zhou; Joerg Berghausen; David Cebrian; Michael Davies; Kevin DeMent; Peter Eddershaw; Arian Emami Riedmaier; Alix F Leblanc; Nenad Manveski; Punit Marathe; Panteleimon D Mavroudis; Robin McDougall; Neil Parrott; Andreas Reichel; Charles Rotter; David Tess; Laurie P Volak; Guangqing Xiao; Zheng Yang; James Baker
Journal:  AAPS J       Date:  2022-07-19       Impact factor: 3.603

4.  Species Differences in Metabolism of Soluble Epoxide Hydrolase Inhibitor, EC1728, Highlight the Importance of Clinically Relevant Screening Mechanisms in Drug Development.

Authors:  Cindy B McReynolds; Jun Yang; Alonso Guedes; Christophe Morisseau; Roberto Garcia; Heather Knych; Caitlin Tearney; Briana Hamamoto; Sung Hee Hwang; Karen Wagner; Bruce D Hammock
Journal:  Molecules       Date:  2021-08-19       Impact factor: 4.411

5.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 6.  Review of nonprimate, large animal models for osteoporosis research.

Authors:  Susan Reinwald; David Burr
Journal:  J Bone Miner Res       Date:  2008-09       Impact factor: 6.741

7.  The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.

Authors:  Leduo Zhang; Yu Mao; Zhiwei Gao; Xiaoyan Chen; Xin Li; Yanjun Liu; Guangxin Xia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

8.  Estimates of the pharmacokinetics of famciclovir and its active metabolite penciclovir in young Asian elephants (Elephas maximus).

Authors:  A Paige Brock; Ramiro Isaza; Robert P Hunter; Laura K Richman; Richard J Montali; Dennis L Schmitt; David E Koch; William A Lindsay
Journal:  Am J Vet Res       Date:  2012-12       Impact factor: 1.156

9.  Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human.

Authors:  Yang Chen; Kaijing Zhao; Fei Liu; Qiushi Xie; Zeyu Zhong; Mingxing Miao; Xiaodong Liu; Li Liu
Journal:  Front Pharmacol       Date:  2016-12-16       Impact factor: 5.810

10.  Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.

Authors:  J Michael Davenport; Paul Covington; Laura Bonifacio; Gail McIntyre; Jürgen Venitz
Journal:  J Clin Pharmacol       Date:  2015-01-14       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.